A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease

Exclusion Criteria

• •Ejection fraction less than 30 percent at screening as determined by echocardiography
• •Progressive angina with symptoms of worsening of angina in the 3 months prior to the first screening examination and/or interventions such as revascularization by percutaneous coronary intervention and or coronary artery bypass graft during the last 3 months
• •Documented current relevant coronary stenosis greater than or equal to 90 percent in any of the main 3 coronary vessels without bypass graft
• •Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis any other moderate or severe valvular failures hypertrophic obstructive cardiomyopathy
• •Symptomatic carotid stenosis or transient ischemic attack or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement
• •Atrial fibrillation pacemaker defibrillator atrial ventricular block II and III
• •History of sustained ventricular tachycardia or ventricular fibrillation within 12 months prior first screening visit
• •History of CNS diseases such as seizures neurodegenerative diseases
• •Lung diseases such as COPD GOLD stage 2-4 pulmonary arterial hypertension or asthma
• •Medical disorder condition or history of such that would impair the participant's ability to participate or complete the study in the opinion of the investigator.